Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 2Teratoma 1Rhabdoid Tumor 1Neuroectodermal Tumors, Primitive 1Meningeal Carcinomatosis 1Medulloblastoma 1Lung Neoplasms 1Infratentorial Neoplasms 1Ependymoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

antineoplaston AS 2-1 4antineoplaston A10 4Cyclophosphamide 4Cisplatin 4Temozolomide 3Radiotherapy 3dactolisib 2Vincristine 2Filgrastim 2Everolimus 2Etoposide 2Bevacizumab 2spartalizumab 1sargramostim 1pasireotide 1ganitumab 1gallium Ga 68 dotatate 1fosbretabulin 1cixutumumab 1belzutifan 1aldesleukin 1Topotecan 1Thiotepa 1TH 302 1Sunitinib 1Standard of Care 1Pregabalin 1Peripheral Blood Stem Cell Transplantation 1Pemetrexed 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroectodermal Tumors, Primitive × Craniospinal Irradiation × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡